Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
11/2003
11/27/2003US20030220256 Truncated 24kDa basic fibroblast growth factor
11/27/2003US20030220248 Use of MP52 or MP121 for the treatment and prevention of diseases of the nervous system
11/27/2003US20030220239 Epitope sequences
11/27/2003US20030220228 Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use
11/27/2003US20030219898 Novel mammalian multipotent stem cells and compositions, methods of preparation and methods of administration thereof
11/27/2003US20030219875 Albumin fusion proteins
11/27/2003US20030219874 Comprises endothelial differentiation gene receptor proteins (EDG8) for monitoring receptivity to and/or diagnosing cancer, angiogenesis and inflammation
11/27/2003US20030219873 Self-assembling recombinant papillomavirus capsid proteins
11/27/2003US20030219864 Novel variants of RANKL protein
11/27/2003US20030219860 Comprises nucleotide sequences coding novel tumor necrosis factor receptor (TRAIN-R) for treating inflammatory bowel disease and arthritic condition; antiinflammatory agents
11/27/2003US20030219789 36P6D5: secreted tumor antigen
11/27/2003US20030219768 Lung cancer therapeutics and diagnostics
11/27/2003US20030219727 Prodrugs of phosphonate nucleotide analogues
11/27/2003US20030219499 Therapy of estrogen-associated disorders
11/27/2003US20030219476 Administering to a mammal a pharmaceutical formulation containing mitoxantrone in a cardiolipin (a liposome), and a excipient to treat cancer and multiple sclerosis
11/27/2003US20030219474 A polynucleotide that hybridizes to a Bcl-2-encoding polynucleotide and a lipid associated with such polynuclotide
11/27/2003US20030219463 Comprises cytotoxic lymphocytes which express CD3-antigen; cytokines
11/27/2003US20030219439 Genetic enginieered mixtures of complementary determining regions(CDR) antigens used for analyzing neutralizing epitopes and for prophylaxis of allergies and respiratory system disorders
11/27/2003US20030219438 Human antibodies that bind human TNFalpha
11/27/2003US20030219426 Endostatins used as antiproliferative agents or angiogenesis inhibitors for prophylaxis of tumors, or as contraceptives
11/27/2003US20030219424 Polynucleotide codes for amino acid sequences used for medical diagnosis, prophylaxis autoimmune diseases, as antiallergens or antitumor agents
11/27/2003US20030219420 Methods for inducing the differentiation of monocytes into functional dendritic cells and immunotherapeutic compositions including such dendritic cells
11/27/2003US20030219419 Alteration of cell membrane for new functions
11/27/2003US20030219411 Modulators of the function of FAS receptors and other proteins
11/27/2003US20030219401 Combination of an aldosterone receptor antagonist and a bile acid sequestering agent
11/27/2003US20030219382 Cancer-linked gene as target for chemotherapy
11/27/2003US20030219379 Antiproliferative agent
11/27/2003US20030219375 Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy
11/27/2003CA2855359A1 Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment and management of multiple myeloma
11/27/2003CA2855306A1 Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment and management of multiple myeloma
11/27/2003CA2812019A1 Recombinant poxvirus expressing homologous genes inserted into the poxviral genome
11/27/2003CA2794297A1 Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione or 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione for treatment and management of amyloidosis
11/27/2003CA2794060A1 Methods and compositions using 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione for treatment and management of multiple myeloma
11/27/2003CA2752140A1 Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydroisoindol-1-yl)-piperidine-2,6-dione for treatment and management of renal cancer
11/27/2003CA2752127A1 Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for treatment and management of hepatocellular carcinoma
11/27/2003CA2752124A1 Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for treatment and management of head and neck cancer
11/27/2003CA2752122A1 Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for treatment and management of ovarian cancer
11/27/2003CA2727830A1 Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment and management of multiple myeloma
11/27/2003CA2727824A1 Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment and management of solid tumors
11/27/2003CA2525672A1 Use of peroxovanadium compounds as tumour cell growth suppressor
11/27/2003CA2493825A1 Means for use in treating diseases correlated with or caused by non-physiological levels of microtubule-associated pp2ac
11/27/2003CA2486583A1 Marker molecules associated with lung tumors
11/27/2003CA2486483A1 Preparation and standardization of immunomodulatory peptide-linked glucans with verifiable oral absorbability from coriolus versicolor
11/27/2003CA2486468A1 Improvements in delivery technology
11/27/2003CA2486327A1 Htlv-i tax induced killing of p53 null cancer cells
11/27/2003CA2486307A1 Drug pre-targeting by means of bi-specific antibodies and hapten constructs comprising a carrier peptide and the active agent(s)
11/27/2003CA2486157A1 Opioid and opioid-like compounds and uses thereof
11/27/2003CA2486141A1 Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
11/27/2003CA2486138A1 Methods of using thiazolidinedithione derivatives
11/27/2003CA2486133A1 Injection formulation
11/27/2003CA2486124A1 Use of docetaxel/doxorubicin/cyclophosphamide in adjuvant therapy of breast and ovarian cancer
11/27/2003CA2486106A1 Compounds and methods for inhibiting selectin-mediated function
11/27/2003CA2486097A1 N-substituted tricyclic 3-aminopyrazoles as pdfg receptor inhibitors
11/27/2003CA2486092A1 Aminotetralin-derived urea modulators of vanilloid vr1 receptor
11/27/2003CA2486028A1 Method of identifying pancreatic ductal carcinoma-specific gene using pancreatic ductal cells, method of testing for pancreatic ductal carcinoma using pancreatic ductal carcinoma-specific gene that is identified by the method, and method of screening pharmaceutical candidate compound for treating or preventing pancreatic ductal carcinoma
11/27/2003CA2486000A1 Use of compounds that are effective as selective opiate receptor modulators
11/27/2003CA2485589A1 Small molecule inhibitors of her2 expression
11/27/2003CA2485367A1 Diaminothiazoles
11/27/2003CA2485214A1 1-oxa-dibenzoazulenes as inhibitors of tumor necrosis factor production and intermediates for the preparation thereof
11/27/2003CA2485081A1 Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic
11/27/2003CA2485012A1 1h-imidazo[4,5-c] quinoline derivatives in the treatment of protein kinase dependent diseases
11/27/2003CA2485006A1 Camptothecin derivatives and polymeric conjugates thereof
11/27/2003CA2484702A1 Substituted 4-aryl-4h-pyrrolo[2,3-h]chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof
11/27/2003CA2484671A1 Cyanoguanidine prodrugs
11/27/2003CA2484324A1 Methods using a combination of a 3-heteroaryl-2-indolinone and a cyclooxygenase-2 inhibitor for the treatment of neoplasia
11/27/2003CA2482756A1 Indole derivatives and the use thereof as cb<sb>2</sb> receptor ligands
11/27/2003CA2482746A1 Combination of a beta-2 adrenoceptor agonists and an aminosugars and their use for the treatment immunomodulatory disorders
11/27/2003CA2481799A1 Recombinant poxvirus expressing homologous genes inserted into the poxviral genome
11/26/2003EP1365246A1 Diagnostics and therapeutics for diseases associated with neuromedin U2 receptor (NMU2)
11/26/2003EP1365242A1 Compounds for detection and treatment of colorectal lesions
11/26/2003EP1365034A2 Methods and compositions for the prediction, diagnosis, prognosis, prevention and treatment of malignant neoplasia
11/26/2003EP1365033A1 Method of molecular diagnosis of chronic myelogenous leukemia
11/26/2003EP1365032A1 Marker molecules associated with lung tumors
11/26/2003EP1365024A1 Traf3-binding b cell-specific receptor
11/26/2003EP1364959A1 Crystal of pyrimidine nucleoside derivative
11/26/2003EP1364953A1 Triazoloquinazoline and pyrazolotriazolopyrimidine derivatives, medicinal compositions, adenosine a3 receptor affinity agents, ocular tension lowering agents, preparations for preventing and treating glaucoma and method of lowering ocular tension
11/26/2003EP1364952A1 Bicyclic nitrogenous fused-ring compound
11/26/2003EP1364949A1 Jnk inhibitor
11/26/2003EP1364660A1 Drug-releasing system of biodegradable polymer type
11/26/2003EP1364657A1 Remedies for tumor in hematopoietic organs
11/26/2003EP1364652A1 Remedies for lung cancer
11/26/2003EP1364069A1 Method for the development of gene panels for diagnostic and therapeutic purposes based on the expression and methylatoin status of the genes
11/26/2003EP1364054A2 Method of determining a chemotherapeutic regimen based on ercc1 expression
11/26/2003EP1364051A2 Screening methods to identify compounds that modulate a response of a cell to ultraviolet radiation exposure
11/26/2003EP1364038A2 Adenovirus particles with mutagenized fiber proteins
11/26/2003EP1364028A2 Regulation of human carboxypeptidase a
11/26/2003EP1364021A2 Compositions and methods relating to colon specific genes and proteins
11/26/2003EP1364014A2 Novx proteins and nucleic acids encoding same. diagnostic and therapeutic uses
11/26/2003EP1364010A2 Immunomodulatory polynucleotides and methods of using the same
11/26/2003EP1363996A2 Epothilone resistant cell lines
11/26/2003EP1363948A1 Polypeptide of a p53 protein-specific murine alpha/beta t-cell receptor, nucleic acids coding therefor and use thereof
11/26/2003EP1363943A2 Interferon regulatory factor-1/human estrogen receptor fusion protein and its use for treating carcinomas
11/26/2003EP1363940A1 Tumour peptide antigen produced from human mdm2 proto-oncogene
11/26/2003EP1363938A2 Molecular vaccine linking an endoplasmic reticulum chaperone polypeptide to an antigen
11/26/2003EP1363934A1 Template-fixed peptidomimetics with antimicrobial activity
11/26/2003EP1363920A1 Modified psma ligands and uses related thereto
11/26/2003EP1363914A1 Aryl substituted alkylcarboxylic acids as hypocholesterolemic agents
11/26/2003EP1363913A2 Salts of pyrimidine derivatives for use against coronary heart disease and atherosclerose
11/26/2003EP1363911A1 Synthesis of temozolomide and analogs
11/26/2003EP1363909A2 Tricyclic androgen receptor modulator compounds
1 ... 1483 1484 1485 1486 1487 1488 1489 1490 1491 1492 1493 1494 1495 1496 1497 1498 1499 1500 1501 1502 1503 ... 2211